Archive
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
BNPP Exane upgrades Currys, says iD Mobile is underappreciated
Thu 28 August 2025 12:44
(Sharecast News) - BNP Paribas Exane upgraded Currys on Thursday to 'outperform' from 'neutral' and lifted the target price to 135p from 115p as it said the iD Mobile business is an underappreciated driver of the company's growth, "enhancing sales, margi
Broker tips: Strix, Trifast, Zotefoams, JD Sports
Wed 27 August 2025 14:50
(Sharecast News) - Analysts at Berenberg initiated coverage on a number of UK capital goods and industrial engineering firms on Wednesday, noting that UK industrials have underperformed the market 11.8% year-to-date, with macroeconomic uncertainty and tar
JD Sports still struggling with LFL declines, but Shore Capital stays positive
Wed 27 August 2025 10:49
(Sharecast News) - JD Sports' update this week revealed that underlying sales continued to struggle in the second quarter, but Shore Capital maintained a 'buy' rating on the stock, citing a "depressed" valuation.
Berenberg initiates trio of UK industrials with 'buy' ratings amid sector underperformance
Wed 27 August 2025 09:37
(Sharecast News) - Analysts at Berenberg initiated coverage on a number of UK capital goods and industrial engineering firms on Wednesday, noting that UK industrials have underperformed the market 11.8% year-to-date, with macroeconomic uncertainty and tar
Broker tips: OXB, Bunzl, AB Foods, Kingfisher, Wickes
Tue 26 August 2025 12:44
(Sharecast News) - Analysts at RBC Capital Markets hiked their target price on gene and cell therapy firm OXB from 800p to 930p on Tuesday following its recent oversubscribed £60m equity funding and revenue guidance reiteration.
RBC Capital Markets raises target price on OXB
Tue 26 August 2025 08:41
(Sharecast News) - Analysts at RBC Capital Markets hiked their target price on gene and cell therapy firm OXB from 800p to 930p on Tuesday following its recent oversubscribed £60m equity funding and revenue guidance reiteration.